Cargando…

Formation of Toxic Oligomeric Assemblies of RNA-binding Protein: Musashi in Alzheimer’s disease

Alzheimer’s disease (AD) is the most common neurodegenerative disorder associated with structural and functional alterations of brain cells causing progressive deterioration of memory and other cognitive functions. Recent studies demonstrate that several neurodegenerative diseases, including AD exhi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sengupta, Urmi, Montalbano, Mauro, McAllen, Salome, Minuesa, Gerard, Kharas, Michael, Kayed, Rakez
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203984/ https://www.ncbi.nlm.nih.gov/pubmed/30367664 http://dx.doi.org/10.1186/s40478-018-0615-0

Ejemplares similares

RNA-binding proteins Musashi and tau soluble aggregates initiate nuclear dysfunction
por: Montalbano, Mauro, et al.
Publicado: (2020)

Tau oligomers mediate aggregation of RNA‐binding proteins Musashi1 and Musashi2 inducing Lamin alteration
por: Montalbano, Mauro, et al.
Publicado: (2019)

Tau oligomer induced HMGB1 release contributes to cellular senescence and neuropathology linked to Alzheimer’s disease and frontotemporal dementia
por: Gaikwad, Sagar, et al.
Publicado: (2021)

Internalization mechanisms of brain-derived tau oligomers from patients with Alzheimer’s disease, progressive supranuclear palsy and dementia with Lewy bodies
por: Puangmalai, Nicha, et al.
Publicado: (2020)

Modulating disease-relevant tau oligomeric strains by small molecules
por: Lo Cascio, Filippa, et al.
Publicado: (2020)

Lysine 63-linked ubiquitination of tau oligomers contributes to the pathogenesis of Alzheimer’s disease
por: Puangmalai, Nicha, et al.
Publicado: (2022)

Pathological tau signatures and nuclear alterations in neurons, astrocytes and microglia in Alzheimer's disease, progressive supranuclear palsy, and dementia with Lewy bodies
por: Montalbano, Mauro, et al.
Publicado: (2022)

Prospects for strain-specific immunotherapy in Alzheimer’s disease and tauopathies
por: Bittar, Alice, et al.
Publicado: (2018)

Tau Modulates mRNA Transcription, Alternative Polyadenylation Profiles of hnRNPs, Chromatin Remodeling and Spliceosome Complexes
por: Montalbano, Mauro, et al.
Publicado: (2021)

Formation and Propagation of Tau Oligomeric Seeds
por: Gerson, Julia E., et al.
Publicado: (2013)

The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy
por: Sengupta, Urmi, et al.
Publicado: (2016)

Characterization of tau oligomeric seeds in progressive supranuclear palsy
por: Gerson, Julia E, et al.
Publicado: (2014)

α-Synuclein Oligomers Induce a Unique Toxic Tau Strain
por: Castillo-Carranza, Diana L., et al.
Publicado: (2018)

The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration
por: Deger, Jennifer M, et al.
Publicado: (2015)

Differential Activation of the ER Stress Factor XBP1 by Oligomeric Assemblies
por: Castillo-Carranza, Diana L., et al.
Publicado: (2012)

Polymorphic Alpha-Synuclein Oligomers: Characterization and Differential Detection with Novel Corresponding Antibodies
por: Moore, Kenya, et al.
Publicado: (2023)

Oligomeric tau-targeted immunotherapy in Tg4510 mice
por: Schroeder, Sulana, et al.
Publicado: (2017)

P53 aggregation, interactions with tau, and impaired DNA damage response in Alzheimer’s disease
por: Farmer, Kathleen M., et al.
Publicado: (2020)

Soluble endogenous oligomeric α-synuclein species in neurodegenerative diseases: Expression, spreading, and cross-talk
por: Kayed, Rakez, et al.
Publicado: (2020)

Tau oligomers in cerebrospinal fluid in Alzheimer's disease
por: Sengupta, Urmi, et al.
Publicado: (2017)

Infectious etiology and amyloidosis in Alzheimer's disease: The puzzle continues
por: Kayed, Rakez
Publicado: (2021)

Polymorphic α-Synuclein Strains Modified by Dopamine and Docosahexaenoic Acid Interact Differentially with Tau Protein
por: Sengupta, Urmi, et al.
Publicado: (2020)

Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy
por: Gerson, Julia E., et al.
Publicado: (2018)

Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia
por: Minuesa, Gerard, et al.
Publicado: (2019)

Aβ/tau oligomer interplay at human synapses supports shifting therapeutic targets for Alzheimer’s disease
por: Marcatti, Michela, et al.
Publicado: (2022)

Neurotoxic tau oligomers after single versus repetitive mild traumatic brain injury
por: Bittar, Alice, et al.
Publicado: (2019)

Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau
por: Lasagna-Reeves, Cristian A., et al.
Publicado: (2012)

The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotypes
por: Lasagna-Reeves, Cristian A, et al.
Publicado: (2014)

Musashi as a Regulator of the Follicle-Stimulating Hormone in the Gonadotropes
por: Silva Moreira, Ana Rita, et al.
Publicado: (2021)

Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice
por: Lasagna-Reeves, Cristian A, et al.
Publicado: (2011)

Elevated phospholipase D isoform 1 in Alzheimer's disease patients' hippocampus: Relevance to synaptic dysfunction and memory deficits
por: Krishnan, Balaji, et al.
Publicado: (2018)

A native interactor scaffolds and stabilizes toxic ATAXIN-1 oligomers in SCA1
por: Lasagna-Reeves, Cristian A, et al.
Publicado: (2015)

SAT-292 Musashi: A Novel Regulator of the Gonadotrope Transcriptome
por: Moreira, Ana Rita Silva, et al.
Publicado: (2020)

OR24-3 Persistence of Progenitor Cell Markers Following the Selective Ablation of Musashi in Somatotropes
por: Allensworth-James, Melody, et al.
Publicado: (2019)

TAU-INDUCED ASTROCYTE SENESCENCE: A NOVEL MECHANISM FOR NEURONAL DYSFUNCTION IN ALZHEIMER’S DISEASE
por: Olson, Angela, et al.
Publicado: (2019)

Cerebral Microvascular Accumulation of Tau Oligomers in Alzheimer’s Disease and Related Tauopathies
por: Castillo-Carranza, Diana L, et al.
Publicado: (2017)

ApoE4-Driven Accumulation of Intraneuronal Oligomerized Aβ42 following Activation of the Amyloid Cascade In Vivo Is Mediated by a Gain of Function
por: Zepa, Lia, et al.
Publicado: (2011)

Immunotherapy for the treatment of Alzheimer’s disease: amyloid-β or tau, which is the right target?
por: Castillo-Carranza, Diana L, et al.
Publicado: (2013)

Alzheimers Disease: Review of Emerging Treatment Role for Intravenous Immunoglobulins
por: Kayed, Rakez, et al.
Publicado: (2011)

Musashi-2 controls cell fate, lineage bias, and TGF-β signaling in HSCs
por: Park, Sun-Mi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_arsmh3doe9ohcjiv65do4rravj